USPTO 2015–2025 USPTO PatentsView US Corporation

Nura BIO, Inc.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company

The verdict

According to USPTO PatentsView, Nura ranks #49,228 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#49,228
of 49,997 US assignees by volume
Top 17%
by Innovation Score (48.3/100)
29.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R49228 · US Corporation #49,228 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #49,228/49,997
  • PHOTO-FINISH Nuformix
  • CPC-NARROW C07D · 4 areas
  • INNOV-PAR 48.3/100
  • CLAIMS-DENSE 29.6 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2023–2025 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Nuformix Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nura’s 48.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Nura

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Nura's Innovation Score is 48.3/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Nura?

Each dot is one of Nura’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nura’s own 29.6 claims/patent is ABOVE the 10.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nura vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 010203040 Granted patents (volume) Avg claims / patent Nuformix Limited - 5, 10.8NuformixNuformix Technologies Limited - 5, 20.2NuformixNumnum, LLC - 5, 9NumnumNuova Ompi S.R.L. Unipersonale - 5, 6Nuova Ompi S R L…Nusil Technology LLC - 5, 18Nusil TechnologyNutjobs - 5, 15.8NutjobsNutrien AG Solutions, Inc. - 5, 14.2Nutrien SolutionsNUU Garden Corporation - 5, 1NUU GardenNura BIO, Inc. - 5, 29.6Nura BIO
Nura vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nura's grants concentrate

Nura BIO, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2023. By volume, Nura sits between Nuformix Limited and NUU Garden Corporation.

Nura's three-year grant acceleration

Nura BIO, Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Nura's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Nura holds 5 patents at rank #49,092, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Nura

By rank, the assignees closest to #49,092 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Nura's primary technology class.

Nura's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202320242025 1
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Nura BIO, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 1 20.0%
2024 3 60.0%
2025partial year 1 20.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Nura BIO, Inc.'s patent record in context - here's where to go next.

  • Nura BIO, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #49,228 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Nura BIO, Inc. against Nuformix Limited, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 48.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.